Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Cancer Biomarkers: Promises and Challenges
share announcement

Cancer Biomarkers: Promises and Challenges

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1474

Special Issue Editor

Dr. Vincenzo Quagliariello

E-Mail Website
Guest Editor
Division of Cardiology, Istituto Nazionale Tumori, IRCCS, Fondazione “G. Pascale”, Naples, Italy
Interests: microenvironment; chemokines; chemoresistance; inflammation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Oncology has evolved with great speed in recent years. The increase in long cancer survivors exposes patients to several clinical, biochemical and cardiological controls aimed to improve the quality of life and reduce the risk of cancer recurrence in patients. A proper biochemical and clinical follow-up is also necessary to reduce cancer-related and anticancer drug-related cardiovascular diseases, which are among the leading causes of death in long survivors. The immunotherapy revolution needs several preclinical and clinical studies on new potential cancer, cardiovascular and cardio-oncology biomarkers.

This Special Issue will focus on studies that identify and describe new putative biomarkers of cancer incidence and recurrence that also involve systemic biomarkers predictive of chemotherapy/radiotherapy/immune check-point inhibitor-induced cardiotoxicity.

Articles on preclinical (cells, mice or rats) or clinical models focused on cancer and/or cardiovascular biomarkers are welcome. These may involve original articles, case-reports, meta-analyses and reviews on different research topics, including novel biomarkers, miRNA, epigenetics, cDNA, proteins, cytokines, chemokines, fatty acids, artificial intelligence, immunotherapy, cardioncology, quality of life in cancer patients, endocrinology in cancer patients, cellular pathways of cancer progression and survival, chemoresistance and immunoresistance.

Dr. Vincenzo Quagliariello
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • cancer
  • cardiooncology
  • immune checkpoint inhibitors
  • inflammation
  • epigenetics
  • proteins
  • cytokines

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

10 pages, 579 KiB  
Review
Navigating HER2-Low Testing in Invasive Breast Cancer: Update Recommendations for Pathologists
by Leticia Bornstein-Quevedo, Jazmín de Anda-González, Cesar Octavio Lara-Torres, Juan Pablo Flores-Gutiérrez, Rita Dorantes-Heredia, Verónica Bautista-Piña, Perla Zaragoza-Vargas, Aldo Alcaraz-Wong, Ana Karen Soto-Sañudo, Saulo Mendoza-Ramírez, Moisés Salamanca-García, Georgina Loyola-Rodríguez, Gabriela Sofia Gómez-Macías, Mario Murguia-Perez, Marcela De Luna-Sánchez, Ricardo Villalobos-Valencia, Enrique Talamantes and Claudia Arce-Salinas
J. Pers. Med. 2024, 14(5), 467; https://doi.org/10.3390/jpm14050467 - 28 Apr 2024
Viewed by 549
Abstract
The article discusses the importance of accurately distinguishing HER2-low from HER2-negative breast cancer, as novel ADCs have demonstrated activity in a large population of patients with HER2-low-expressing BC. While current guidelines recommend a dichotomous classification of HER2 as either positive or negative, the [...] Read more.
The article discusses the importance of accurately distinguishing HER2-low from HER2-negative breast cancer, as novel ADCs have demonstrated activity in a large population of patients with HER2-low-expressing BC. While current guidelines recommend a dichotomous classification of HER2 as either positive or negative, the emergence of the HER2-low concept calls for standardization of HER2 testing in breast cancer, using currently available assays to better discriminate HER2 levels. This review covers the evolution and latest updates of the ASCO/CAP guidelines relevant to this important biomarker in breast cancer, including still-evolving concepts such as HER2 low, HER2 heterogeneity, and HER2 evolution. Our group presents the latest Mexican recommendations for HER2 status evaluation in breast cancer, considering the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, accurate HER2 status assessment remains one of the most important biomarkers in breast cancer, and the commitment of Mexican pathologists to theragnostic biomarker quality is crucial for providing the most efficient care in oncology. Full article
(This article belongs to the Special Issue Cancer Biomarkers: Promises and Challenges)
►▼ Show Figures

Figure 1

27 pages, 845 KiB  
Review
Clinical Application of Different Liquid Biopsy Components in Hepatocellular Carcinoma
by Jing Xu, Yuanyuan Zhao, Zhishui Chen and Lai Wei
J. Pers. Med. 2024, 14(4), 420; https://doi.org/10.3390/jpm14040420 - 15 Apr 2024
Viewed by 716
Abstract
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, usually occurring in the background of chronic liver disease. HCC lethality rate is in the third highest place in the world. Patients with HCC have concealed early symptoms and possess a [...] Read more.
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, usually occurring in the background of chronic liver disease. HCC lethality rate is in the third highest place in the world. Patients with HCC have concealed early symptoms and possess a high-level of heterogeneity. Once diagnosed, most of the tumors are in advanced stages and have a poor prognosis. The sensitivity and specificity of existing detection modalities and protocols are suboptimal. HCC calls for more sophisticated and individualized therapeutic regimens. Liquid biopsy is non-invasive, repeatable, unaffected by location, and can be monitored dynamically. It has emerged as a useable aid in achieving precision malignant tumor treatment. Circulating tumor cells (CTCs), circulating nucleic acids, exosomes and tumor-educated platelets are the commonest components of a liquid biopsy. It possesses the theoretical ability to conquer the high heterogeneity and the difficulty of early detection for HCC patients. In this review, we summarize the common enrichment techniques and the clinical applications in HCC for different liquid biopsy components. Tumor recurrence after HCC-related liver transplantation is more insidious and difficult to treat. The clinical use of liquid biopsy in HCC-related liver transplantation is also summarized in this review. Full article
(This article belongs to the Special Issue Cancer Biomarkers: Promises and Challenges)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop